# What a combination label can establish about the material inside

- Article ID: research-086
- Product: CJC-1295 (No DAC) / Ipamorelin (cjc-1295-ipamorelin-578)
- Canonical page: https://heritagebiolabs.com/research-library/articles/086-what-a-combination-label-can-establish-about-the-material-inside
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-no-dac-ipamorelin
- Product page: https://heritagebiolabs.com/product/cjc-1295-ipamorelin-578
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains linked by peptide bonds. They can imitate biological signals, and changes to either chain in a mixture can matter to how that mixture behaves. CJC-1295 (No DAC) / Ipamorelin names a 29-residue modified growth hormone–releasing factor and a separate five-residue agonist of the ghrelin receptor. Which parts of that identity can a catalog label establish? [1, 2]

An April 2026 advisory from Australia's Therapeutic Goods Administration listed products containing CJC-1295 among examples of unapproved peptide goods. The agency described uncertainty about the ingredients, manufacturing and sterility of such products, and pointed out that labels can be inaccurate. The advisory addressed a regulatory category of products. It did not report a chemical analysis of a specific no-DAC and ipamorelin preparation. [3]

The FDA's older substance assessments explain a distinction behind the names. The no-DAC form lacks the drug affinity complex that is attached to the longer-acting CJC-1295 molecule. Ipamorelin and its acetate salt were evaluated as separate bulk substances. A label naming the two intended active peptides leaves open the exact chemical forms, the amount of each and whether the preparation contains other substances or degradation products. [1, 2]

No recent primary study identifying and following the two compounds in the exact catalog mixture was identified. Chemical characterization could verify what is present in a tested sample, while a controlled biological experiment would answer a different question about its effects. The regulatory records cover the quality and evidence issues they reviewed. They provide no independent verification of the contents or clinical performance of this pairing. [1, 2, 3]

## Sources

1. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>
2. U.S. Food and Drug Administration. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee. FDA briefing document on ipamorelin-related bulk drug substances (publication 2024-10-29). <https://www.fda.gov/media/182088/download>
3. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. TGA safety advisory (publication 2026-04-13). <https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 018 - CJC-1295 (No DAC) Ipamorelin.docx; article 86; content SHA-256 2f99561cccc92821fb591dc518f07311c5832219a636b890b853d4120417b9bf.
